泰格醫藥(300347.SZ)擬1億元認繳合夥企業出資額
格隆匯2月26日丨泰格醫藥(300347.SZ)公佈,公司擬以自有資金投資湖州富悦柏澤實業投資合夥企業(有限合夥)(“合夥企業”)。合夥企業認繳出資總額預計為人民幣3.20億元,公司擬認繳出資額為人民幣1億元。
公司此次投資合夥企業,可以結合公司在醫藥臨牀研究領域的專業優勢,拓展公司投資渠道,獲取投資收益。同時該合作模式也將幫助公司提升綜合服務能力,發展優質項目儲備。此次投資短期內對公司財務狀況和經營成果不會造成重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.